In this clinical trial, 90 participants with stage III to IV unresectable melanoma received a peptide vaccine and various doses of nivolumab (1 to 10 mg/kg with Montanide ISA 51 VG) in the presence or absence of peptide-based vaccination (gp100/MART-1/NY-ESO-1 with Montanide). Here, PMEL is linked to melanoma.